Stockwatch

Date	Sym	Type	Headline
2024-05-01 07:30	UU:OCUL	News Release200	Ocular Therapeutix(TM) to Host Investor Day in New York City on Thursday, June 13, 2024
2024-04-18 07:00	UU:OCUL	News Release200	Ocular Therapeutix(TM) Announces Positive Topline Phase 1 Data for AXPAXLI(TM) in Diabetic Retinopathy
2024-04-16 07:00	UU:OCUL	News Release200	Ocular Therapeutix(TM) Strengthens Clinical Team with Appointment of Key Retinal Leaders
2024-04-15 07:00	UU:OCUL	News Release200	Ocular Therapeutix(TM) Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
2024-04-09 07:30	UU:OCUL	News Release200	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
2024-04-06 10:00	UU:OCUL	News Release200	Ocular Therapeutix(TM) Announces Positive Phase 2 PAXTRAVA(TM) Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
2024-03-26 07:30	UU:OCUL	News Release200	Ocular Therapeutix(TM) To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
2024-03-11 16:05	UU:OCUL	News Release200	Ocular Therapeutix(TM) Reports Fourth Quarter and Full Year 2023 Results
2024-03-05 07:30	UU:OCUL	News Release200	Ocular Therapeutix(TM) to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
2024-02-22 07:32	UU:OCUL	News Release200	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer
2024-02-22 07:31	UU:OCUL	News Release200	Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
2024-02-22 07:30	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ Announces Board of Directors and Leadership Updates
2024-02-19 09:00	UU:OCUL	News Release200	AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA ‚ ® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctiv
2024-02-15 08:00	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ Appoints Steve Meyers to Chief Commercial Officer
2024-02-13 07:38	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI ¢ „ ¢ in Wet AMD
2024-01-25 08:00	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI ¢ „ ¢ in Wet AMD
2023-12-18 16:01	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
2023-12-13 22:10	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ Announces Pricing of Public Offering of Common Stock
2023-12-13 16:01	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ Announces Proposed Public Offering of Common Stock
2023-11-08 08:00	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ to Present at Three Upcoming Investor Conferences
2023-11-07 16:01	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ Provides Third Quarter 2023 Financial Results and Corporate Update
2023-11-01 08:00	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
2023-10-31 09:00	UU:OCUL	News Release200	AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA ‚ ® in Patients after Cataract Surgery
2023-10-24 08:00	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ To Report Third Quarter 2023 Financial Results
2023-10-03 16:01	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
2023-09-06 08:00	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ to Present at Three Upcoming Investor Conferences
2023-08-09 08:00	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
2023-08-07 16:01	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ Provides Second Quarter 2023 Financial Results and Corporate Update
2023-07-24 08:00	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ To Report Second Quarter 2023 Financial Results
2023-07-12 08:00	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ Announces Appointment of New Board Member
2023-06-10 18:30	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD
2023-06-07 08:00	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy
2023-06-05 16:01	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting
2023-06-01 08:00	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ to Present at the Jefferies Global Healthcare Conference
2023-05-08 16:01	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ Provides First Quarter 2023 Financial Results and Corporate Update
2023-05-08 08:00	UU:OCUL	News Release200	Ocular Therapeutix ¢ „ ¢ to Present at the JMP Securities Life Sciences Conference